CA-RIX-INDUSTRIES
RIX Industries (“RIX”), a leading developer of pneumatic energy technology, announced today that it has licensed proprietary methanol-based M-Series hydrogen generator technology from Element 1 Corp (e1). Under the terms of the license agreement, RIX has been granted rights to manufacture and deploy e1’s M-Series on-board hydrogen generators for use in fuel cell mobility applications, including marine vessels and off-road vehicles such as mining trucks, tractors, and heavy-lift trucks in both North America and Europe.
Governments across the globe are striving to reduce harmful emissions into the air and waterways. Tightening regulations combined with corporate sustainability initiatives are driving a massive migration to non-polluting electric propulsion systems, many of which utilize hydrogen fuel cells. RIX’s history of supporting the maritime industry, including the US Navy, together with e1’s methanol to hydrogen generator offers end-users an opportunity to adopt fuel cell motive solutions and work towards a zero-emissions future.
“RIX Industries has a global reputation for excellence and the addition of e1’s class-leading technology to our portfolio strategically aligns with our brand and our growth strategy,” said Bryan Reid, Chief Sales Officer at RIX. “We are focused on the clean energy future and firmly believe that there is a significant market opportunity that can be effectively addressed by RIX incorporating e1’s M-Series hydrogen generator into power solutions.”
Dr. David Edlund, e1 CEO, said, “e1 is delighted and privileged to be collaborating with RIX. They are a first-class manufacturing partner and a long-time authorized supplier to multiple branches of the U.S. military along with a wide range of commercial and industrial end-users. The on-board hydrogen generation technology being licensed to RIX is unique to e1 and is highly enabling to the mass commercialization of fuel cell systems for a wide variety of transportation-related fuel cell applications. I anticipate our relationship with RIX to broaden substantially over the not too distant future,” concluded Dr. Edlund.
The onboard storage of methanol used by e1’s hydrogen generators requires a fraction of the space on a maritime vessel as compared to compressed hydrogen, enabling a significantly greater range between fueling. This range extension is critical for not only marine vessels but also for heavy and medium-duty fuel cell trucks traveling long distances each day.
About RIX Industries:
Founded in 1878, RIX Industries is a technology-focused company, headquartered in Benicia, CA, specializing in the design, development and manufacture of pneumatic energy storage, transfer and control system solutions, including gas generation systems, precision compressor solutions and cryogenic cooling technologies for critical applications in Marine, Aerospace, Land, Energy, Industrial and Medical markets.
Visit www.CreateCompressCool.com for more information.
About Element 1 Corporation:
Element 1 designs and develops novel processes to enable the commercialization of clean-energy products and processes and alternative-energy technology. Through licensing our IP to strategic partners, our mission is to significantly reduce barriers to the adoption of hydrogen technology and fuel cells for a range of applications and to reduce the waste and pollution associated with flaring natural gas.
For more information about Element 1, please visit www.e1na.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005856/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom